See the PhD Opportunities section to see if this project is currently open for applications via MIBTP.
Please Note: The main page lists projects via BBSRC Research Theme(s) quoted and then relevant Topic(s).
Host-pathogen compatibility in TB: defining how M.tuberculosis lineage and human ancestry shape TB phenotype, transmission and immune control
Secondary Supervisor(s): Prof Adam Cunningham
University of Registration: University of Birmingham
BBSRC Research Themes:
Project Outline
The Mycobacterium tuberculosis complex (MTBC) includes several human-adapted M.tuberculosis (Mtb) lineages with distinct global distributions. L4 (Euro-American) is a widespread generalist, whereas L5 and L6 are restricted to West Africa, suggesting host-pathogen co-adaptation. Matching between Mtb lineage and host ancestry is sympatry; infection with a lineage from a non-overlapping region is allopatry.
Mtb lineage may influence TB phenotype and outcomes. L1 has been linked to extra-pulmonary TB, osteomyelitis and cavitary disease, while outcomes also reflect host factors including age, nutrition, HIV and diabetes. Post-tuberculosis lung disease (PTLD) is a major sequela and WHO research priority. However, the effect of sympatry and allopatry on phenotype, immunology and PTLD remains poorly understood, although limited data suggest allopatric East Asian and Euro-American infections may cause greater pulmonary impairment. Experimental studies suggest ancestry-lineage interactions shape immune responses, with lineage-dependent differences in macrophage uptake, replication and inflammation. Current evidence is limited by small samples, restricted populations, narrow lineage coverage and low-resolution typing, making whole genome sequencing essential.
This project will investigate how Mtb sympatry and allopatry influence transmission, phenotype, outcomes and host immunity. We will analyse national UK WGS-linked datasets over 10 years to estimate TB rates and clinical associations and assess drug resistance, disease site, severity, treatment response, PTLD, transmission and contact immune responses. We will then use ex vivo and in vitro models in healthy donors of defined ancestry, challenging whole blood and immune cells subsets with related and unrelated Mtb lineages and measure mycobacterial control, cytokine responses, immune phenotypes and spatial transcriptomic networks. Potential benefits include advancing TB biology, risk prediction, outcomes and targeted care.